-
公开(公告)号:US20170197938A1
公开(公告)日:2017-07-13
申请号:US15326698
申请日:2015-07-17
申请人: ABIVAX , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT CURIE , UNIVERSITE DE MONTPELLIER
发明人: Jamal TAZI , Romain NAJMAN , Florence MAHUTEAU , Didier SCHERRER , Aude GARCEL , Noëlie CAMPOS
IPC分类号: C07D401/12
CPC分类号: C07D401/12
摘要: The present invention relates to a compound of formula (1) in the form of a base or addition salt with an acid, particularly a pharmaceutically acceptable acid. It further relates to a pharmaceutical composition including the compound and at least one pharmaceutically acceptable excipient, to a process for preparing said compound and to a corresponding intermediate compound.
-
公开(公告)号:US20160151348A1
公开(公告)日:2016-06-02
申请号:US14902935
申请日:2014-07-04
申请人: ABIVAX , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT CURIE , UNIVERSITE DE MONTPELLIER
发明人: Jamal TAZI , Florence MAHUTEAU-BETZER , Romain NAJMAN , Didier SCHERRER , Noëlie CAMPOS , Aude GARCEL
IPC分类号: A61K31/4709 , A61K31/497 , A61K31/498 , A61K31/47
CPC分类号: A61K31/4709 , A61K31/47 , A61K31/497 , A61K31/498 , A61K31/506
摘要: Methods for preventing or treating retroviral infection not HIV and/or for preventing, inhibiting or treating a disease caused by the retroviral infection include contacting a cell with compound (I) wherein: means a pyridazine, pyrimidine or pyrazine group, R independently represent a hydrogen atom, halogen atom or group chosen among a —CN, hydroxyl, —COOR1, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy and (C1-C3)alkyl group, the alkyl being optionally mono-substituted by hydroxyl group, n is 1, 2 or 3, n′ is 1 or 2, R′ is a hydrogen atom, halogen atom or group chosen among (C1-C3)alkyl group, hydroxyl group, —COOR1 group, —NO2 group, —NR1R2 group, morpholinyl or morpholino group, N-methylpiperazinyl group, (C1-C3)fluoroalkyl group, (C1-C4)alkoxy group and —CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C.
摘要翻译: 用于预防或治疗逆转录病毒感染而不是HIV和/或用于预防,抑制或治疗由逆转录病毒感染引起的疾病的方法包括使细胞与化合物(I)接触,其中:表示哒嗪,嘧啶或吡嗪基,R独立地表示氢 原子,卤素原子或选自-CN,羟基,-COOR1,(C1-C3)氟烷基,(C1-C3)氟烷氧基,-NO2,-NR1R2,(C1-C4)烷氧基,苯氧基和(C1-C3) )烷基,烷基任选被羟基单取代,n为1,2或3,n'为1或2,R'为氢原子,卤素原子或选自(C1-C3)烷基中的基团 ,羟基,-COOR1基,-NO2基,-NR1R2基,吗啉基或吗啉基,N-甲基哌嗪基,(C1-C3)氟烷基,(C1-C4)烷氧基和-CN基,Z是N或 C,Y为N或C,X为N或C,W为N或C,T为N或C,U为N或C。
-
公开(公告)号:US20150361491A1
公开(公告)日:2015-12-17
申请号:US14761674
申请日:2014-01-17
发明人: Jamal TAZI , Didier SCHERRER , Aude GARCEL , Noëlie CAMPOS , Romain NAJMAN , Florence MAHUTEAU-BETZER
CPC分类号: C12Q1/6876 , C12Q1/70 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178
摘要: A use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker, in particular of a viral infection, or of an efficacy of a therapeutic treatment of said viral infection.
摘要翻译: 使用至少一种miRNA,所述至少一种miRNA是miR-124,作为生物标志物,特别是病毒感染,或治疗性治疗所述病毒感染的功效。
-
-